Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published ...

Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

NEW YORK - Debate over the need for COVID-19 booster shots is clouding the outlook for Moderna Inc's high-flying shares after ...

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...